Endometrial Cancer
820
208
267
303
Key Insights
Highlights
Success Rate
82% trial completion
Published Results
83 trials with published results (10%)
Research Maturity
303 completed trials (37% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.9%
65 terminated out of 820 trials
82.3%
-4.2% vs benchmark
6%
52 trials in Phase 3/4
27%
83 of 303 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 303 completed trials
Clinical Trials (820)
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
Integrated Cancer Repository for Cancer Research
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
DESTINY-PANTUMOUR04
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
REal Word aPpLicAtion of Molecular Based Endometrial Cancer Classification
Tirzepatide in Obesity-Driven Endometrial Cancer
Social Interventions for Support During Treatment for Endometrial Cancer and Recurrence
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors